Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2012

View Archived Issues

New Wnt/catenin beta signaling inhibitor shows potential as cancer therapy

Durable submental fat reduction seen with ATX-101

Novel mTOR inhibitors reported

Merck KGaA develops novel inhibitors of tyrosine-protein kinases

GSK discloses new chemokine CCR4 receptor antagonists

U.S. university presents new vaccines for dengue

Peptide vaccine to enter phase IIa study

Hyperion Therapeutics acquires rights to Ravicti

Bioabsorbable stent shows promise in patients with coronary artery disease

Toray evaluates 11-beta-HSD1 inhibitor in obesity and diabetes models

New product extends therapeutic window of t-PA in stroke model

Coronado Biosciences signs agreement with Dr. Falk Pharma and OvaMed

GSK and Theravance complete registrational program

Byetta obtains European approval as add-on therapy to basal insulin

Medgenics receives clearance for phase IIa study in patients on dialysis

Mitsubishi Tanabe revises prescribing information for Imusera

NeuroDiscovery provides company update

Applications submitted for once-monthly risedronate sodium hydrate in Japan

Novel FLAP and leukotriene synthesis inhibitors patented

NeoPharm presents new protease-activated PAR2 receptor antagonists

Bionomics clear to initiate phase I/II trial of BNC-105

Kyorin Pharmaceutical reports novel AMPK activators

Pivotal LEAP trial reaches target enrollment

Endocyte receives approval for nonproprietary names of anticancer drug and companion imaging agent

EMA validates Raptor's MAA for RP-103

EMA to review Vivus' MAA for avanafil in ED

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...